Beyond very early systemic sclerosis: deciphering prescleroderma and its trajectories to open new avenues for preventive medicine.
Lancet Rheumatol
; 5(11): e683-e694, 2023 Nov.
Article
en En
| MEDLINE
| ID: mdl-38251534
ABSTRACT
The identification of individuals with systemic sclerosis in an oligosymptomatic phase preceding the very early manifestations of the disease represents a challenge in the search for a new window of opportunity in systemic sclerosis. This phase could be identified in a clinical scenario as the pre-scleroderma phase, in which the disease would still be far from systemic sclerosis-related fibrotic or irreversible manifestations in skin or organs. In this Personal View, we discuss parameters and candidate definitions for a conceptual framework of pre-scleroderma, from the identification of populations at risk to autoantibodies and their potential functional activities. We discuss how this new paradigm of pre-scleroderma could represent a game-changing approach in the management of systemic sclerosis, allowing the treatment of patients at high risk of organ involvement or skin fibrosis before such events occur.
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Esclerodermia Localizada
/
Esclerodermia Sistémica
/
Basidiomycota
Tipo de estudio:
Diagnostic_studies
/
Prognostic_studies
Límite:
Humans
Idioma:
En
Revista:
Lancet Rheumatol
Año:
2023
Tipo del documento:
Article